Skip to content
StockMarketAgent
Direct answer
Stryker is a high-quality mature compounder with a durable moat derived from high switching costs, scale economies, and deep hospital relationships across MedSurg and Orthopaedics. The continued adoption of Mako robotics provides a strong catalyst for market share gains and implant pull-through. Fair value range: low $225, high $370, with mid-point at $297.
Stock analysis

SYK fair value $225–$370

By StockMarketAgent.AI team· supervised by
Analizado: 2026-05-12Próxima actualización: 2026-08-12Methodology v2.5Review: automatedArchetype: Mature compounder
View archive
Precio
$294.45
▲ +2.93 (+1.00%)
Valor razonable
$297
$225–$370
Calificación
Mantener
confidence 88/100
Potencial alcista
+1.0%
upside to fair value
Margen de seguridad
$252.77
MoS level · 15%
Capitalización bursátil
$112.8B
P/E fwd 17.6
Respaldo en inglésES
Mostrando la fuente en inglés mientras traducimos
Este informe aún no se ha traducido. Actualice en unos minutos una vez que la cola de traducción se ponga al día.

§1 Resumen ejecutivo

  • Stryker benefits from high switching costs and Mako ecosystem lock-in.
  • Fair value mid-point of $297.38 implies only 1% upside, prompting a Hold.
  • Trades at a massive premium to peers (PEG 2.51), posing severe multiple contraction risk if growth slows.
  • Watch Mako placement volumes and 20.5% operating margin stability.
Fair value
$297
Margin of safety
+1.0%
Confidence
88/100
Moat
9/10

Educational research only - not investment advice, an offer, or a trade instruction. Confirm current data and do your own due diligence before acting.

$294.45Price
Low $225.47
Mid $297.38
High $370.47

Stryker is a high-quality mature compounder with a durable moat derived from high switching costs, scale economies, and deep hospital relationships across MedSurg and Orthopaedics. The continued adoption of Mako robotics provides a strong catalyst for market share gains and implant pull-through.

  • High switching costs in hospital
    High switching costs in hospital ecosystems
  • Scale economies in MedSurg and
    Scale economies in MedSurg and Orthopaedics
  • Cycle upside
    Accelerating hospital capital expenditures and aging demographics driving elective procedure volumes.

§2 Caso bajista

A sustained hospital CapExCapital expendituresCash spent on acquiring or upgrading property, plant, and equipment. Splits into maintenance capex (sustaining current capacity) and growth capex (expanding capacity). freeze slows Mako placements, while aggressive GPO negotiations compress implant ASPs, pushing operating margins below 19% and compressing the multiple.

Cómo puede fallar esta tesis

Multiple Contraction to Peer Median

· Medium

SYK's PEG of 2.51 compresses to the med-tech peer median of 1.56 as Mako-driven growth normalizes.

FV impact
-25%
Trigger
12-24 Months

Orthopaedic Pricing Collapse

· Low

Hospital GPOs successfully leverage increased competition to drive down orthopaedic implant pricing.

FV impact
-15%
Trigger
24-36 Months

Robotics CapEx Freeze

· Medium

Macroeconomic pressures severely constrain hospital capital expenditure budgets, halting Mako placements.

FV impact
-20%
Trigger
6-18 Months
Señales de alerta temprana a vigilar
MétricaActualUmbral de activación
Two consecutive quarters of operating margin falling below 19%.MonitorDeterioration versus the report thesis
Multi-quarter deceleration in Mako placement volumes.MonitorDeterioration versus the report thesis
Explicit pushback on orthopedic implant ASPs from major GPOs.MonitorDeterioration versus the report thesis
Multiple contraction closer to the peer PEG ratio.MonitorDeterioration versus the report thesis
Deceleration in MedSurg equipment cross-selling.MonitorDeterioration versus the report thesis

§3 Historial financiero

Cuenta de resultados — últimos seis períodos

Concepto2022-12-312023-12-312024-12-312025-12-31Trend
Ingresos$18.45B$20.50B+11.1%$22.60B+10.2%$25.12B+11.2%+10.8%
Beneficio bruto$11.58B$13.06B$14.44B$16.07B+11.5%
Beneficio operativo$3.11B$3.92B$4.67B$5.06B+17.6%
Beneficio neto$2.36B$3.17B+34.3%$2.99B-5.7%$3.25B+8.7%+11.2%
BPA (diluido)$6.17$8.25$7.76$8.40+10.8%
EBITDA$4.11B$5.06B$4.95B$6.31B+15.4%
I+D$1.45B$1.39B$1.47B$1.62B+3.7%
SG&A$6.39B$7.11B$7.69B$8.65B+10.6%

Puntuaciones de calidad

OCF / Beneficio neto
1.55×
>1 indica alta calidad de los beneficios
Umbral de calidad contable
Fail
Umbral ajustado por sector
ROIC
10.6%
Rentabilidad del capital invertido
Suscriptores individuales — desde §411 secciones más

Leer el análisis completo — 11 secciones más.

Competitive moat, industry cycle, peer comparison, intrinsic valuation, sensitivity, scenarios, earnings decision tree, position management, investor perspectives, scorecard, and final recommendation.

Informe completo para cada ticker cubierto
24 meses de archivo de calificaciones
Briefings de lista de seguimiento + alertas de cambio de calificación
Exportación PDF + DOCX en cualquier idioma
Comenzar prueba gratuita
Cancela cuando quieras.
INCOME STATEMENT FAQ

SYK income statement questions

  1. Our financial-history view of SYK (SYK) covers revenue, gross profit, operating income, and net income across the past five fiscal years, with year-over-year growth and margin context for each line.
FAQ

SYK — frequently asked questions

  1. Based on our latest analysis, SYK trades close to fair value. The current price is $294 versus a composite fair-value midpoint of $297 (range $225–$370), which implies roughly 1.0% upside to the midpoint.
Related coverage

Names readers of SYK also follow

Same archetype: mature-compounder